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Abstract
Background: Coronary heart disease is increasing in urban Indian subjects and lipid abnormalities
are important risk factors. To determine secular trends in prevalence of various lipid abnormalities
we performed studies in an urban Indian population.
Methods:  Successive epidemiological Jaipur Heart Watch (JHW) studies were performed in
Western India in urban locations. The studies evaluated adults ≥ 20 years for multiple coronary risk
factors using standardized methodology (JHW-1, 1993–94, n = 2212; JHW-2, 1999–2001, n = 1123;
JHW-3, 2002–03, n = 458, and JHW-4 2004–2005, n = 1127). For the present analyses data of
subjects 20–59 years (n = 4136, men 2341, women 1795) have been included. In successive studies,
fasting measurements for cholesterol lipoproteins (total cholesterol, LDL cholesterol, HDL
cholesterol) and triglycerides were performed in 193, 454, 179 and 252 men (n = 1078) and 83,
472, 195, 248 women (n = 998) respectively (total 2076). Age-group specific levels of various
cholesterol lipoproteins, triglycerides and their ratios were determined. Prevalence of various
dyslipidemias (total cholesterol ≥ 200 mg/dl, LDL cholesterol ≥ 130 mg/dl, non-HDL cholesterol ≥
160 mg/dl, triglycerides ≥ 150 mg/dl, low HDL cholesterol <40 mg/dl, high cholesterol remnants ≥
25 mg/dl, and high total:HDL cholesterol ratio ≥ 5.0, and ≥ 4.0 were also determined. Significance
of secular trends in prevalence of dyslipidemias was determined using linear-curve estimation
regression. Association of changing trends in prevalence of dyslipidemias with trends in educational
status, obesity and truncal obesity (high waist:hip ratio) were determined using two-line regression
analysis.
Results: Mean levels of various lipoproteins increased sharply from JHW-1 to JHW-2 and then
gradually in JHW-3 and JHW-4. Age-adjusted mean values (mg/dl) in JHW-1, JHW-2, JHW-3 and
JHW-4 studies respectively showed a significant increase in total cholesterol (174.9 ± 45, 196.0 ±
42, 187.5 ± 38, 193.5 ± 39, 2-stage least-squares regression R = 0.11, p < 0.001), LDL cholesterol
(106.2 ± 40, 127.6 ± 39, 122.6 ± 44, 119.2 ± 31, R = 0.11, p < 0.001), non-HDL cholesterol (131.3
± 43, 156.4 ± 43, 150.1 ± 41, 150.9 ± 32, R = 0.12, p < 0.001), remnant cholesterol (25.1 ± 11, 28.9
± 14, 26.0 ± 11, 31.7 ± 14, R = 0.06, p = 0.001), total:HDL cholesterol ratio (4.26 ± 1.3, 5.18 ± 1.7,
5.21 ± 1.7, 4.69 ± 1.2, R = 0.10, p < 0.001) and triglycerides (125.6 ± 53, 144.5 ± 71, 130.1 ± 57,
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158.7 ± 72, R = 0.06, p = 0.001) and decrease in HDL cholesterol (43.6 ± 14, 39.7 ± 8, 37.3 ± 6,
42.5 ± 6, R = 0.04, p = 0.027). Trends in age-adjusted prevalence (%) of dyslipidemias in JHW-1,
JHW-2, JHW-3 and JHW-4 studies respectively showed insignificant changes in high total
cholesterol (26.3, 35.1, 25.6, 26.0, linear curve-estimation coefficient multiple R = 0.034), high LDL
cholesterol ≥ 130 mg/dl (24.2, 36.2, 31.0, 22.2, R = 0.062), and high low HDL cholesterol < 40 mg/
dl (46.2, 53.3, 55.4, 33.7, R = 0.136). Increase was observed in prevalence of high non-HDL
cholesterol (23.0, 33.5, 27.4, 26.6, R = 0.026), high remnant cholesterol (40.1, 40.3, 30.1, 60.6, R =
0.143), high total:HDL cholesterol ratio ≥ 5.0 (22.2, 47.6, 53.2, 26.3, R = 0.031) and ≥ 4.0 (58.6,
72.5, 70.1, 62.0, R = 0.006), and high triglycerides (25.7, 28.2, 17.5, 34.2, R = 0.047). Greater
correlation of increasing non-HDL cholesterol, remnant cholesterol, triglycerides and total:HDL
cholesterol ratio was observed with increasing truncal obesity than generalized obesity (two-line
regression analysis p < 0.05). Greater educational level, as marker of socioeconomic status,
correlated significantly with increasing obesity (r2 men 0.98, women 0.99), and truncal obesity (r2
men 0.71, women 0.90).
Conclusion: In an urban Indian population, trends reveal increase in mean total-, non-HDL-,
remnant-, and total:HDL cholesterol, and triglycerides and decline in HDL cholesterol levels.
Prevalence of subjects with high total cholesterol did not change significantly while those with high
non-HDL cholesterol, cholesterol remnants, triglycerides and total-HDL cholesterol ratio
increased. Increasing dyslipidemias correlate significantly with increasing truncal obesity and
obesity.
Introduction
Cardiovascular diseases, especially coronary heart disease,
are important public health problems in India and many
developing countries [1,2]. There is evidence that the dis-
eases are increasing in these countries in contrast to devel-
oped nations of Europe and North America where the
incidence has decreased [3,4]. Societal changes as well as
individual lifestyle factors are important in driving this
cardiovascular epidemic [5]. These changes influence the
proximate determinants of atherosclerosis which include
smoking and tobacco use, high total and low density lipo-
protein (LDL) cholesterol, low high density lipoprotein
(HDL) cholesterol, high blood pressure, diabetes and the
metabolic syndrome. Trends of these risk factors have
been well studied in developed countries and show signif-
icant correlation with rise and fall of the coronary heart
disease epidemic [5].
There have been only a few studies that have examined
trends in cardiovascular risk factors in middle and low
income countries [6]. In Seven Countries Study multiple
cross sectional surveys were conducted among men aged
40–59 years in Yugoslavia, Italy, Greece, Holland, Fin-
land, Japan and USA [7]. These studies reported that while
major coronary risk factors initially stabilized and later
declined in many of these countries, in middle income
countries such as Yugoslavia the risk factors increased. The
WHO-MONICA study reported that population risk fac-
tors increased in the Chinese while they declined in North
American and Western European cohorts [8,9]. Increasing
trends in coronary risk factors has also been reported from
many middle income Latin American countries [6]. In
Asia, increasing trends in lipids and in prevalence of dysl-
ipidemias (high LDL cholesterol and low HDL choles-
terol) has been reported in urban populations of Beijing
[10], rural China [11] and South Korea [12].
To our knowledge no single study that systematically eval-
uated trends in major cardiovascular risk factors in India
exists although reviews have reported increasing preva-
lence of hypertension [13], diabetes [14], and hypercho-
lesterolemia [2], and declining smoking rates among the
educated Indians [15]. All these evaluations suffer from
multiple biases inherent in compiling studies from differ-
ent sources and different methodologies [16]. We per-
formed multiple coronary heart disease risk factor
epidemiological studies in urban populations in western
Indian state of Rajasthan to determine their lifestyle and
other determinants [17-20]. Here we report trends in lev-
els of various lipoproteins (total, LDL, HDL and non-HDL
cholesterol, triglycerides) and total-HDL cholesterol ratio
and prevalence of dyslipidemias using current definitions.
Methods
A series of cross sectional epidemiological studies using
similar tools in the Indian state of Rajasthan over years
1992–2005 were performed to determine cardiovascular
risk factors in urban populations [17-20]. All the studies
were approved by the institutional ethics committee and
supported financially by different organizations. The
studies have been performed in Jaipur, the capital city of
Rajasthan state in western India with population in year
2001 of 2.34 million. The first study – Jaipur Heart Watch
(JHW)-1 [17], was conducted in years 1993–1994 andLipids in Health and Disease 2008, 7:40 http://www.lipidworld.com/content/7/1/40
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randomly selected 1608 men and 1392 women were tar-
geted using stratified cluster sampling on the Voters' lists
in six locations in Jaipur city. 2212 subjects (1415 men
88.0%, 797 women 57.3%) were evaluated for various
cardiovascular risk factors and attempt for fasting blood
sample for cholesterol lipoproteins and triglycerides was
in 15%. In the second urban study (JHW-2) [18] we tar-
geted 960 men and 840 women in the same locations as
in JHW-1 and could examine 550 men (57.3%) and 573
women (68.2%). In this study we targeted all the partici-
pants for the fasting blood sample. The third (JHW-3)
[19] and fourth (JHW-4) [20] urban studies targeted at a
smaller sample and were designed to gather information
on risk factors in middle-class locations. Response rates
are shown in Table 1.
Data collection
Methodological details have been previously reported
[17]. Briefly, we collected information regarding demo-
graphic data, educational level, history of chronic illnesses
such as coronary heart disease, hypertension, diabetes or
high cholesterol levels, and smoking or tobacco intake.
Brief questions were asked to evaluate physical activity
and diet but the results were considered inadequate and
not included in the analyses. Physical examination was
performed to assess height, weight, waist and hip size and
blood pressure. BMI was calculated as weight (kg) divided
by squared height (m). Waist-to-hip ratio was calculated.
Fasting glucose was determined at a central laboratory
using glucose peroxidase method and external quality
control. Total cholesterol was measured using cholesterol
oxidase-phenol 4-aminophenazone peroxidase method
and HDL cholesterol using an enzymatic method after
precipitating non-HDL cholesterol with a managanese-
heparin substrate. Triglycerides were measured using the
glycerol phosphate oxidase-peroxidase enzymatic
method. Quality control measures were followed for esti-
mation of total cholesterol, high density lipoprotein
(HDL) cholesterol and triglycerides while low density
lipoprotein (LDL) cholesterol was estimated using the
Friedewald formula [21].
Diagnostic criteria
The diagnostic criteria for coronary risk factors have been
advised by the American College of Cardiology clinical
data standards [22]. Educational level was used as marker
for socioeconomic status as reported in an earlier study
[23]. More than 5 years of formal education (primary edu-
cation or more) was taken as acceptable literacy level for
analysis. Obesity or overweight was defined as body mass
index of ≥ 25 kg/m2 and truncal obesity was defined by
waist:hip ratio of > 0.95 for men and > 0.85 for women
[24]. Dyslipidemia was defined by the presence of high
total cholesterol (≥ 200 mg/dl), high LDL cholesterol (≥
130 mg/dl), low HDL cholesterol (< 40 mg/dl), high non-
HDL cholesterol (≥ 160 mg/dl), high cholesterol rem-
nants [very low density lipoprotein cholesterol = total –
(HDL+LDL) cholesterol ≥ 25 mg/dl] or high triglycerides
(≥ 150 mg/dl) according to National Cholesterol Educa-
tion Program (NCEP) Adult Treatment Panel-3 (ATP-3)
guidelines [25]. High total to HDL cholesterol was
defined when ratio was either ≥ 5.0 or ≥ 4.0 as reported in
an earlier study from India [26].
Statistical analyses
The continuous variables are reported as mean ± 1 SD and
ordinal variables in percent. Prevalence rates are reported
in percent. Age-stratified prevalence rates and distribution
of various risk factors have been reported for decadal
intervals from 20 years 59 years. Age-adjustment of vari-
ous prevalence rates was performed using direct method
using the Jaipur urban population according to 2001 cen-
sus. Correlation of age with lipid values was performed by
simple correlation analysis and significance of age-
adjusted trends in mean lipoprotein levels was evaluated
by 2-stage least squares regression using SPSS 10.0 statis-
tical package (SPSS Inc, Chicago). Significance of trends in
prevalence rates was determined using linear curve-esti-
mation regression analysis using the SPSS package.
Regression coefficients are reported as multiple R values
after age adjustment. Significance of graphical trends was
determined by logarithmic regression analysis using the
Microsoft Office Power Point (2002) program. Signifi-
Table 1: Demographic characteristics of various Jaipur Heart Watch studies
Study Years performed 
(Published)
Target sample size
Age ≥ 20 years
Study subjects
Age ≥ 20 years
Total subjects
Age 20–59 years
Blood samples in enrollees
Age 20–59 years
Men Women Men Women Men Women Men Women
JHW-1 1993–1995 (1995) 1608 1392 1415 (88.0) 797 (57.2) 1294 655 193 (14.9) 83 (12.7)
JHW-2 1999–2001 (2002) 960 840 532(55.4) 559(66.5) 454 472 454(100.0) 472 (100.0)
JHW-3 2001–2002 (2004) 320 280 226 (70.6) 232 (82.9) 179 195 179 (100.0) 195 (100.0)
JHW-4 2004–2005 (2007) 750 650 556 (74.1) 571 (87.8) 414 473 252 (60.9) 248 (52.4)
Total N = 6790 3638 3152 2729 (75.0) 2159 (68.5) 2341 1795 1078 (46.0) 998 (55.6)
JHW Jaipur Heart Watch. Numbers in parentheses are percent response rates. Blood samples obtained for lipid profile estimation.Lipids in Health and Disease 2008, 7:40 http://www.lipidworld.com/content/7/1/40
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cance of two-line trends was determined by least squares
regression analyses using GB-Stat for Windows® software
7.0 (Dynamic Microsystems Inc, Silver Spring, MD USA)
and reported as r2 values. The r2 values of more than 0.10
and p values less than 0.05 were considered significant.
Results
The overall response rates in the study were 2747/3638
(76.5%) in men and 2173/3152 (68.5%) in women. Of
the 4146 subjects aged 20–59 years (men 2341, women
1795), blood samples were obtained in 1078 (46.0%)
men and 998 (55.6%) women (total = 2076, 50.1%).
Response rates varied in different studies (Table 1).
Mean levels of various lipoproteins at different age-groups
are shown in Table 2. There is age-associated escalation in
total cholesterol, LDL cholesterol, non-HDL cholesterol,
remnant cholesterol, total:HDL cholesterol ratio and trig-
lycerides in men and women in all the cohorts. The levels
of HDL cholesterol decline with age, the decline being
similar in men and women. Correlation of various lipo-
proteins with age in combined data from JHW studies is
shown in Figure 1. There is a significant increase in total
cholesterol (r = 0.16), LDL cholesterol (r = 0.15), non-
HDL cholesterol (r = 0.16), total:HDL cholesterol ratio (r
= 0.13)and triglycerides (r = 0.07) with age (p < 0.001 for
all). HDL cholesterol decreases slightly with age (r = -0.05,
p = 0.02). Trends in men and women are almost similar
and hence not reported separately. Comparison of levels
across studies reveals increase in all lipid levels from JHW-
1 to JHW-2 studies but are not significantly different in
JHW-3 and JHW-4 studies. Age-adjusted trends in mean
lipoprotein values (mg/dl) in JHW-1, JHW-2, JHW-3 and
JHW-4 studies respectively show a significant increase in
total cholesterol (174.9 ± 45, 196.0 ± 42, 187.5 ± 38,
193.5 ± 39, 2-stage least-squares regression R = 0.11, p <
0.001), LDL cholesterol (106.2 ± 40, 127.6 ± 39, 122.6 ±
44, 119.2 ± 31, R = 0.11, p < 0.001), non-HDL cholesterol
(131.3 ± 43, 156.4 ± 43, 150.1 ± 41, 150.9 ± 32, R = 0.12,
p < 0.001), remnant cholesterol (25.1 ± 11, 28.9 ± 14,
26.0 ± 11, 31.7 ± 14, R = 0.06, p = 0.001), total:HDL cho-
lesterol (4.26 ± 1.3, 5.18 ± 1.7, 5.21 ± 1.7, 4.69 ± 1.2, R =
0.10, p < 0.001) and triglycerides (125.6 ± 53, 144.5 ± 71,
130.1 ± 57, 158.7 ± 72, R = 0.06, p = 0.001) and decrease
in HDL cholesterol (43.6 ± 14, 39.7 ± 8, 37.3 ± 6, 42.5 ±
6, R = 0.04, p = 0.027) (Figure 2).
Prevalence of dyslipidemias categorized according to the
ATP-3 report [25] is shown in Table 3. In all cohorts the
prevalence of various forms of lipid abnormalities
increased with age. There is a sharp increase in dyslipi-
demia prevalence from JHW-1 to JHW-2 study. Curve-esti-
mation regression analysis shows significant increase in
non-HDL cholesterol, remnant cholesterol, triglycerides
and total:HDL cholesterol. Graphical trends in age-
adjusted prevalence (%) of dyslipidemias in JHW-1, JHW-
2, JHW-3 and JHW-4 studies respectively show (Figure 3)
insignificant changes in high total cholesterol (23.7, 35.1,
27.1, 26.1, least squares regression r2 0.02), high LDL cho-
lesterol ≥ 130 mg/dl (21.9, 36.2, 31.1, 22.1, r2 0.13), and
low HDL cholesterol < 40 mg/dl (42.9, 53.3, 55.4, 33.7, r2
0.02). Significant increase is observed in prevalence of
high non-HDL cholesterol (20.8, 33.5, 27.4, 26.6, r2
0.20), high remnant cholesterol (40.1, 40.3, 30.1, 60.6, r2
0.15), high total:HDL cholesterol ratio (≥ 5.0: 20.1, 47.6,
53.2, 26.4, r2 0.15 and ≥ 4.0: 60.5, 74.4, 77.7, 66.6, r2
0.12) and high triglycerides (22.8, 28.2, 17.5, 34.2, r2
0.13). Secular trends in men (data not shown) reveal sig-
nificant increase in prevalence of high non-HDL choles-
terol (r20.22), high remnant cholesterol (r2 0.34), high
total:HDL cholesterol and ≥ 4.0 (r2 0.28), and high triglyc-
erides (r2 0.31) while in women prevalence of high non-
HDL cholesterol (r2 0.11) increased and that of low HDL
cholesterol < 40 mg/dl decreased (r20.38).
We correlated changing lipid levels with socioeconomic
status and generalized and truncal obesity. Educational
level has been used as marker of socioeconomic status
[23] and the age-adjusted prevalence of literacy greater
than primary education (> 5 years of formal education) in
successive studies increased significantly in men (66.4,
83.0, 98.4, 90.7, r2 0.69) as well as women (30.3, 67.8,
99.1, 87.5, r2 0.75). Significantly increasing trends in over-
weight or obesity (r2 men 0.84, women 0.78) as well as
truncal obesity (r2 men 0.28, women 0.20) in different
JHW cohorts were also observed [24]. Cross correlation
analysis using two-line regression revealed that increasing
educational status correlated significantly with obesity (r2
men 0.98, women 0.99) as well as truncal obesity (r2 men
0.71, women 0.90). For various lipoprotein lipids a two-
line regression analysis reveals more significant relation-
ship of truncal obesity as compared to generalized obesity
with various lipid parameters (Table 4). Increasing truncal
obesity correlates significantly with high total cholesterol
(r2 0.77, p = 0.011), LDL cholesterol (r2 0.74, p = 0.014),
non-HDL cholesterol (r2 0.88, p = 0.003), and total:HDL
cholesterol ≥ 5.0 (r2 0.59, p = 0.037) and ≥ 4.0 (r2 0.77, p
= 0.011). Obesity correlates weakly with increasing LDL
cholesterol (r2 0.46, p = 0.069), non-HDL cholesterol (r2
0.42, p = 0.082), total:HDL cholesterol ratio ≥ 5 (r2 0.46,
p = 0.071) and total:HDL cholesterol ratio ≥ 4 (r2 0.48, p
= 0.061) (Table 4).
Discussion
This study shows that there is a high prevalence of various
forms of lipoprotein abnormalities in Indian urban sub-
jects. Secular trends reveal increasing mean levels of total-
, LDL-, non HDL-, and remnant cholesterol, total:HDL
cholesterol ratio and triglycerides and decline in HDL
cholesterol. Prevalence of high non-HDL cholesterol,Lipids in Health and Disease 2008, 7:40 http://www.lipidworld.com/content/7/1/40
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Correlation of various cholesterol lipoproteins and triglycerides with age in combined data from JHW studies Figure 1
Correlation of various cholesterol lipoproteins and triglycerides with age in combined data from JHW studies. 
There is a significant increase in total cholesterol (r = 0.16), LDL cholesterol (r = 0.15), non-HDL cholesterol (r = 0.16), total: 
HDL cholesterol ratio (r = 0.13) and triglycerides (r = 0.07) with age (p < 0.001 for all). HDL cholesterol decreases slightly 
with age (r = -0.05, p = 0.02). Trends in men and women are almost similar and not reported separately.
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Box-plot of mean and median values (mg/dl) and 95% confidence intervals of various cholesterol lipoproteins and triglycerides  in various Jaipur Heart Watch Studies Figure 2
Box-plot of mean and median values (mg/dl) and 95% confidence intervals of various cholesterol lipoproteins 
and triglycerides in various Jaipur Heart Watch Studies. There is a significant increase in trends of age-adjusted levels 
of total cholesterol (2-stage least-squares regression R = 0.11, p < 0.001), LDL cholesterol (R = 0.11, p < 0.001), non-HDL 
cholesterol (R = 0.12, p < 0.001) and total: HDL cholesterol (R = 0.10, p < 0.001) and triglycerides (R = 0.06, p = 0.001) and 
decrease in HDL cholesterol (R = 0.04, p = 0.027).
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remnant cholesterol, and total-HDL cholesterol ratio
increased. These changes correlate significantly with
increasing education (socioeconomic status) and truncal
obesity. Most of the lipid abnormalities are markers of
dietary excess, low physical activity and increasing obesity
[27]. The present study confirms that increasing obesity
manifest as truncal obesity, due to population-wide sed-
entary lifestyle and high calorie intake [28,29], leads to
increase in multiple dyslipidemias. We have previously
reported increase in prevalence of coronary heart disease
[2] in urban Indian populations and the present study
suggests that increasing non-HDL cholesterol, cholesterol
remnants, and total-HDL cholesterol ratio are important
risk factors. The importance of these dyslipidemias has
been highlighted in multiple prospective studies from
other countries [30-32].
Rise and fall of cholesterol and other lipoproteins associ-
ated with changing cardiovascular mortality and coronary
heart disease incidence has been well documented in
Table 2: Age-specific levels of cholesterol lipoproteins and triglycerides (mg/dl)
Men Women
Lipid parameters in mg/dl JHW-1 JHW-2 JHW-3 JHW-4 JHW-1 JHW-2 JHW-3 JHW-4
Numbers 193 454 179 252 83 472 195 248
Cholesterol
20–29 163.9 ± 29 180.6 ± 35 167.1 ± 35 184.9 ± 29 174.0 ± 35 180.0 ± 33 171.4 ± 24 183.3 ± 19
30–39 182.1 ± 41 200.1 ± 47 189.6 ± 49 192.9 ± 25 174.9 ± 48 192.6 ± 41 193.1 ± 41 192.5 ± 48
40–49 183.6 ± 44 196.6 ± 43 194.7 ± 47 188.8 ± 28 161.9 ± 31 196.9 ± 37 194.7 ± 47 198.9 ± 49
170.7 ± 68 200.1 ± 41 200.3 ± 32 201.5 ± 31 190.8 ± 90 208.9 ± 45 200.3 ± 32 216.3 ± 53
LDL cholesterol
20–29 99.4 ± 27 113.7 ± 32 105.6 ± 27 110.5 ± 6 100.0 ± 30 114.3 ± 33 105.6 ± 27 112.4 ± 21
30–39 114.2 ± 38 127.1 ± 40 125.2 ± 46 116.5 ± 33 98.1 ± 37 126.2 ± 38 125.2 ± 46 119.3 ± 42
40–49 111.7 ± 44 128.1 ± 43 131.6 ± 49 110.1 ± 31 102.3 ± 42 130.3 ± 33 131.6 ± 49 123.0 ± 42
50–59 98.0 ± 52 129.5 ± 37 132.7 ± 34 127.4 ± 31 122.8 ± 71 137.1 ± 45 132.7 ± 34 138.3 ± 46
HDL cholesterol
20–29 41.7 ± 12 40.5 ± 9 37.7 ± 8 43.0 ± 5 52.6 ± 22 41.6 ± 9 38.7 ± 5 44.7 ± 6
30–39 43.8 ± 10 39.1 ± 9 35.3 ± 8 41.3 ± 4 40.5 ± 11 38.9 ± 8 36.3 ± 6 42.6 ± 4
40–49 44.4 ± 11 38.3 ± 8 35.6 ± 5 43.0 ± 7 45.6 ± 15 38.5 ± 9 35.5 ± 5 42.7 ± 4
50–59 43.4 ± 20 40.1 ± 8 36.6 ± 5 39.6 ± 7 40.2 ± 15 41.2 ± 8 36.6 ± 5 42.6 ± 4
Non HDL cholesterol
20–29 122.5 ± 30 140.1 ± 36.0 132.7 ± 24.8 141.9 ± 27.9 121.4 ± 34 138.4 ± 35.7 126.9 ± 31.4 138.6 ± 20.0
30–39 138.3 ± 41 161.0 ± 48.5 156.7 ± 43.1 151.6 ± 29.9 121.3 ± 35 153.7 ± 41.5 143.7 ± 35.8 142.8 ± 29.5
40–49 139.0 ± 43 159.9 ± 40.8 159.1 ± 49.5 145.7 ± 31.7 129.3 ± 45 158.2 ± 36.9 150.0 ± 35.6 145.1 ± 31.5
50–59 127.3 ± 56 150.7 ± 41.5 163.7 ± 34.8 161.8 ± 29.4 150.6 ± 79 167.7 ± 46.8 153.8 ± 44.8 164.2 ± 40.3
Total:HDL cholesterol ratio
20–29 4.17 ± 1.0 4.67 ± 1.4 4.52 ± 0.9 4.38 ± 0.9 3.67 ± 1.3 4.53 ± 1.33 4.26 ± 1.3 4.17 ± 0.7
30–39 4.30 ± 1.1 5.40 ± 2.0 5.51 ± 1.7 4.87 ± 1.4 4.27 ± 1.4 5.19 ± 1.7 4.97 ± 1.5 4.45 ± 1.0
40–49 4.30 ± 1.2 5.37 ± 1.9 5.71 ± 2.2 4.54 ± 1.2 4.10 ± 1.4 5.28 ± 1.45 5.19 ± 1.4 4.55 ± 1.3
50–59 4.24 ± 1.4 5.18 ± 1.5 5.65 ± 1.5 5.27 ± 1.5 4.81 ± 1.4 5.29 ± 1.7 5.29 ± 1.7 5.03 ± 1.4
Triglycerides
20–29 113.8 ± 56 131.8 ± 51 118.8 ± 42 157.3 ± 72 106.8 ± 41 120.1 ± 40 121.9 ± 38 130.8 ± 36
30–39 120.6 ± 48 169.5 ± 107 145.6 ± 118 175.6 ± 76 116.3 ± 46 137.3 ± 70 148.6 ± 117 153.1 ± 62
40–49 137.2 ± 50 150.8 ± 76 137.5 ± 57 178.0 ± 91 135.0 ± 42 140.9 ± 65 137.5 ± 57 161.2 ± 75
50–59 146.4 ± 75 152.2 ± 67 154.9 ± 63 172.2 ± 102 139.3 ± 57 153.2 ± 68 155.0 ± 63 176.5 ± 79
Remnant cholesterol
l20–29 22.6 ± 11 26.4 ± 10 27.1 ± 19 31.5 ± 15 21.4 ± 8 24.0 ± 8 30.6 ± 51 26.1 ± 7
30–39 24.1 ± 10 33.9 ± 22 31.5 ± 26 35.1 ± 18 23.3 ± 9 27.5 ± 14 25.1 ± 18 29.9 ± 11
40–49 27.4 ± 10 30.2 ± 15 27.5 ± 11 35.6 ± 20 27.0 ± 8 27.9 ± 14 30.7 ± 45 30.4 ± 13
50–59 29.3 ± 15 30.4 ± 13 31.0 ± 13 34.3 ± 19 27.9 ± 11 30.6 ± 14 27.1 ± 12 31.4 ± 10Lipids in Health and Disease 2008, 7:40 http://www.lipidworld.com/content/7/1/40
Page 8 of 13
(page number not for citation purposes)
Trends in age-adjusted prevalence of various dyslipidemias in various Jaipur Heart Watch (JHW) studies Figure 3
Trends in age-adjusted prevalence of various dyslipidemias in various Jaipur Heart Watch (JHW) studies. 
Graphic analysis shows that prevalence (%) of high total cholesterol ≥ 200 mg/dl (logarithmic r2 = 0.026), high LDL cholesterol 
≥ 130 mg/dl (r2 = 0.001), low HDL cholesterol < 40 mg/dl (r2 = 0.091) and triglycerides (r2 = 0.033) did not change significantly. 
Prevalence of non-HDL cholesterol ≥ 160 mg/dl (r2 = 0.089), remnant cholesterol ≥ 25 mg/dl (r2 = 0.155), and total: HDL cho-
lesterol ≥ 4.0 (r2 = 0.120) and ≥ 5.0 (r2 = 0.112) increased.
26.3
35.1
25.6 26
y = -1.1828Ln(x) + 29.19
R
2 = 0.0242
0
5
10
15
20
25
30
35
40
45
JHW-1 JHW-2 JHW-3 JHW-4
Cholesterol >=200
24.2
36.2
31
22.2
y = -0.3063Ln(x) + 28.643
R
2 = 0.0008
0
5
10
15
20
25
30
35
40
45
JHW-1 JHW-2 JHW-3 JHW-4
LDL Cholesterol >=130
23
33.5
27.4 26.6
y = 2.2174Ln(x) + 25.863
R
2 = 0.0935
0
5
10
15
20
25
30
35
40
45
J H W - 1J H W - 2J H W - 3J H W - 4
Non HDL Cholesterol >=160
46.2
53.3 55.4
33.7
y = -4.9061Ln(x) + 51.048
R
2 = 0.0907
0
10
20
30
40
50
60
JHW-1 JHW-2 JHW-3 JHW-4
HDL Cholesterol <40
22.2
47.6
53.2
26.3
y = 8.558Ln(x) + 30.526
R
2 = 0.1122
0
10
20
30
40
50
60
70
J H W - 1J H W - 2J H W - 3J H W - 4
Total/HDL >=5
58.6
72.5 70.1
62
y = 3.7817Ln(x) + 62.795
R
2 = 0.1196
0
10
20
30
40
50
60
70
80
J H W - 1J H W - 2J H W - 3J H W - 4
Total/HDL >=4
25.7 28.2
17 .5
34.2
y = 2.1058Ln(x) + 24.727
R
2 = 0.0334
0
5
10
15
20
25
30
35
40
45
JHW-1 JHW-2 JHW-3 JHW-4
Triglycerides >=150
40.1 40.3
30.1
60.6
y = 8.3658Ln(x) + 36.128
R
2 = 0.1543
-5
5
15
25
35
45
55
65
JHW-1 JHW-2 JHW-3 JHW-4
Remnant Cholesterol >=25Lipids in Health and Disease 2008, 7:40 http://www.lipidworld.com/content/7/1/40
Page 9 of 13
(page number not for citation purposes)
many developed countries [7,8,25]. There is paucity of
similar data from developing countries. Data of the
present study has significant healthcare policy and phar-
macoeconomic implications because more than 40% of
the world's population is in India and China. A econo-
mies of these countries boom [33] and individual buying
capacity increases the lifestyle changes shall lead to mas-
sive increase in lipid levels fuelling cardiovascular epi-
demic as observed in the present study in an Indian urban
population.
Table 3: Age-specific prevalence rates (%) and trends in dyslipidaemia in various studies
Lipid Parameters JHW-1
(n = 276)
JHW-2
(n = 926)
JHW-3
(n = 374)
JHW-4
(n = 500)
Linear curve-estimation regression 
coefficient. Multiple R
(p value)
Cholesterol ≥200 mg/dl
20–29 12 (17.6) 46 (24.6) 11 (13.4) 16 (17.0) 0.034 (0.088)
30–39 30 (29.1) 107 (36.9) 29 (27.1) 36 (28.8)
40–49 24 (34.3) 103 (43.3) 41 (38.3) 41 (27.5)
50–59 12 (34.3) 107 (50.7) 31 (39.7) 60 (45.5)
Age adjusted, 95% CI 26.3 (20.1–32.5) 35.1 (32.0–38.2) 25.6 (21.1–30.0) 26.0 (22.1–29.8)
LDL cholesterol ≥130 mg/dl
20–29 9 (13.2) 50 (26.7) 14 (17.1) 15 (16.0) 0.062 (0.002)
30–39 35 (34.0) 111 (38.3) 40 (37.4) 32 (25.6)
40–49 21 (30.0) 101 (42.4) 42 (39.3) 28 (18.8)
50–59 9 (25.7) 108 (51.2) 36 (46.2) 52 (39.4)
Age adjusted, 95% C 24.2 (18.1–30.2) 36.2 (33.1–39.3) 31.0 (26.3–35.7) 22.2 (18.6–25.8)
HDL cholesterol < 40 mg/dl
20–29 36 (52.9) 90 (48.1) 48 (58.5) 23 (24.5) 0.136 (< 0.001)
30–39 42 (40.8) 166 (57.2) 57 (53.3) 51 (40.8)
40–49 29 (41.4) 144 (60.5) 58 (54.2) 58 (38.9)
50–59 16 (45.7) 103 (48.8) 41 (52.6) 49 (37.1)
Age adjusted, 95% CI 46.2 (40.3–52.1) 53.3 (50.1–56.6) 55.4 (52.2–58.6) 33.7 (29.6–37.8)
Non-HDL cholesterol ≥160 mg/dl
20–29 10 (14.7) 41 (21.9) 11 (13.4) 19 (20.2) 0.026 (0.196)
30–39 31 (30.1) 106 (36.5) 32 (29.9) 36 (28.8)
40–49 20 (28.6) 100 (42.0) 43 (40.2) 41 (27.5)
50–59 8 (22.9) 104 (49.3) 35 (44.9) 53 (40.2)
Age adjusted, 95% CI 23.0 (18.0–28.0) 33.5 (30.5–36.5) 27.4 (22.9–31.9) 26.6 (22.7–30.5)
Total/HDL ratio ≥5.0
20–29 12 (17.6) 67 (35.8) 31 (37.8) 16 (17.0) 0.031 (0.123)
30–39 23 (22.3) 155 (53.4) 62 (57.9) 39 (31.2)
40–49 19 (27.1) 135 (56.7) 72 (67.3) 37 (24.8)
50–59 10 (28.6) 118 (55.9 53 (67.9) 62 (47.0)
Age adjusted, 95% CI 22.2 (17.3–27.1) 47.6 (44.4–50.8) 53.2 (48.1–58.3) 26.3 (22.4–30.2)
Total/HDL ratio ≥4.0
20–29 41 (60.3) 119 (63.6) 46 (56.1) 51 (54.3) 0.006 (0.756)
30–39 64 (62.1) 221 (76.2) 82 (76.6) 83 (66.4)
40–49 33 (47.1) 191 (80.3) 86 (80.4) 90 (60.4)
50–59 21 (63.6) 166 (78.7) 64 (82.1) 104 (78.8)
Age adjusted, 95% CI 58.6 (52.8–64.4) 72.5 (69.6–75.4) 70.1 (65.5–74.7) 62.0 (57.8–66.3)
Triglycerides ≥150 mg/dl
20–29 11 (16.2) 38 (20.3) 11 (13.4) 24 (25.5) 0.047 (0.019)
30–39 24 (23.3) 97 (33.4) 17 (15.9) 49 (39.2)
40–49 26 (37.1) 71 (29.8) 23 (21.5) 60 (40.3)
50–59 15 (42.9) 80 (37.9) 22 (28.2) 52 (39.4)
Age adjusted, 95% CI 25.7 (19.5–31.8) 28.2 (25.3–31.1) 17.5 (13.7–21.4) 34.2 (30.0–38.3)
Remnant cholesterol ≥25 mg/d
20–29 20 (29.4) 55 (29.4) 18 (22.0) 48 (51.1) 0.143 (< 0.001)
30–39 38 (36.9) 135 (46.6) 30 (28.0) 85 (68.01)
40–49 40 (57.1) 105 (44.1) 41 (38.3) 97 (65.1)
50–59 19 (54.3) 112 (53.1) 37 (47.4) 87 (65.9)
Age adjusted, 95% CI 40.1 (34.3–45.9) 40.3 (37.1–43.4) 30.1 (25.4–34.7) 60.6 (56.4–64.9)Lipids in Health and Disease 2008, 7:40 http://www.lipidworld.com/content/7/1/40
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In China two large scale surveys have been carried out to
determine prevalence of lipid abnormalities [34,11]. The
first survey in 1992 reported greater lipid values in urban
as compared to rural populations [34]. Among 9477 sub-
jects the mean ± SD cholesterol at urban sites in China was
181.6 ± 32 to 184.8 ± 38 mg/dl in men and 187.5 ± 33 to
187.6 ± 42 in women. The values were 15–25 mg lower in
rural subjects [34]. Prevalence of hypercholesterolemia ≥
200 mg/dl was 29.1–31.0% in urban subjects and 7.7–
20.0% rural subjects. Second survey in 2004 was a popu-
lation based epidemiological study among 15540 adults
and reported mean ± SEM cholesterol of 193.0 ± 0.7 in
urban men and 196.4 ± 0.7 in urban women [11]. These
levels were significantly greater than the 1992 study. This
study also reported lower urban-rural gap in cholesterol
levels (10–11 mg/dl more in the urban). Age-adjusted
prevalence of hypercholesterolemia was 39.8% in urban
men, 44.1% in urban women, 30.2% in rural men and
31.7% in rural women. Age-adjusted prevalence rates for
hypercholesterolemia are lower in our study (Table 3).
Prevalence of low HDL cholesterol < 40 mg/dl in Chinese
urban subjects were 29.5% in men and 14.6% in women
aged 35–74 years which is lower than reported in our sub-
jects. These studies did not report prevalence of hypertrig-
lyceridemia or high total:HDL cholesterol ratios. Another
study from China reported changing trends of cardiovas-
cular risk factors in different socioeconomic groups but
did not comment on lipid levels [35]. The Korea National
Health and Nutrition Examination Survey (2001) in sub-
jects 20–79 years reported mean cholesterol of 187.8 ± 33
mg/dl in men and 185.3 ± 34 mg/dl in women, HDL cho-
lesterol of 44.1 ± 10 mg/dl in men and 48.5 ± 10 mg/dl in
women, and triglycerides of 155.1 ± 83 in men and 118.8
± 68 mg/dl in women [12]. Prevalence of hypercholester-
olemia ≥ 240 mg/dl was in 7.1% men and women while
low HDL cholesterol levels < 35 mg/dl were in 35.1% men
and 17.8% women. These results are similar to studies
from China and prevalence of low HDL cholesterol is less
than our studies. In a study in 417 Mexican cities among
2256 of 15607 enrolled subjects, 20–69 years, mean cho-
lesterol was 182.7 mg/dl, triglycerides 213.4 mg/dl, HDL
cholesterol 38.3 mg/dl and LDL cholesterol 116.4 mg/dl
[36]. Prevalence of hypercholesterolemia was in 27.1%,
low HDL, defined by ATP-3 guidelines, in 48.4% and
hypertriglyceridemia in 42.3% in men and women. These
values are similar to our studies. We have used cut-off for
diagnosis of low HDL cholesterol in consonance with the
Asian studies to make the data regionally comparable. The
ATP-3 guidelines [25] suggest different HDL cholesterol
thresholds for men (< 40 mg/l) and women (< 50 mg/dl).
We analysed data based on cut-off of < 40 mg/dl because
when the cut-off of < 50 mg/dl was used more than 90%
of study subjects fell in dyslipidemia category. On the
other hand in Sub-Saharan African countries very low
mean population total cholesterol levels, 140–160 mg/dl,
and very high HDL cholesterol levels, 50–65 mg/dl have
been reported [37]. Dietary and other lifestyle habits
could be a factor as in traditional hunter-gatherer popula-
tions similar findings have been reported [38].
Secular trends in cholesterol lipoproteins in developed
countries reveal a decline in mean serum total cholesterol
and LDL cholesterol levels. In USA, periodical cross sec-
tional surveys from 1960–2002 have reported that mean
± SEM total cholesterol in adults 20–74 years decreased
from 222 ± 1.5 mg/dl in 1960–62, to 216 ± 0.8 in 1971–
74, 215 ± 1.1 in 1976–80, 204 ± 0.7 in 1988–1994 ad 203
± 0.9 mg/dl in 1999–2002 [39]. Values of other lipids
were reported in latter studies and as compared from years
1976–80 to 1999–2002 levels of LDL cholesterol declined
from 138 mg/dl to 123 mg/dl, HDL cholesterol levels
increased from 49.7 mg/dl to 51.0 mg/dl and triglyceride
levels increased from 114 mg/dl to 122 mg/dl. Age-
adjusted prevalence of hypercholesterolemia ≥ 240 mg/dl
decreased from 20 ± 0.6% during 1988–1994 to 17 ±
0.6% during 1999–2002. Similar declines in population
cholesterol levels and prevalence of hypercholesterolemia
has been reported from North American and Western
European cohorts of Seven Countries Study [7]. The
decline in total and LDL cholesterol has been attributed to
documented decreases in dietary intake of saturated fats
and cholesterol [40]. However, recent evidence suggests
that the decline in USA may have been due to increased
use of medications rather than positive lifestyle changes
Table 4: Two-line regression analysis (r2, and p value) of association of high educational status (> primary education), obesity (BMI ≥ 25 
kg/m2) and truncal obesity (waist:hip > 0.9) with various lipid parameters.
Lipid variable Educational status Obesity Truncal obesity
Total Cholesterol ≥ 200 mg/dl 0.450 (0.072) 0.322 (0.120) 0.773 (0.011)
LDL Cholesterol ≥ 130 mg/dl 0.529 (0.051) 0.462 (0.069) 0.737 (0.014)
HDL Cholesterol < 40 mg/dl 0.347 (0.109) 0.352 (0.107) 0.477 (0.064)
Non-HDL Cholesterol ≥ 160 mg/dl 0.531 (0.050) 0.421 (0.082) 0.884 (0.003)
Remnant cholesterol ≥ 25 mg/dl -0.211 (0.179) -0.257 (0.152) -0.0711 (0.305)
Total:HDL cholesterol ratio ≥ 5.0 0.469 (0.067) 0.456 (0.071) 0.593 (0.037)
Total:HDL cholesterol ratio ≥ 4.0 0.535 (0.049) 0.480 (0.061) 0.768 (0.011)
Triglycerides ≥ 150 mg/dl -0.111 (0.259) -0.196 (0.189) 0.099 (0.272)Lipids in Health and Disease 2008, 7:40 http://www.lipidworld.com/content/7/1/40
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[40]. It is also suggested that the slower decline in recent
years is likely due to increase in obesity among adults and
the observed increase in triglyceride levels is a marker
[39]. In the present study too, it is observed that increas-
ing obesity is important determinant of increases in total,
non-HDL, and LDL cholesterol and triglycerides. This
augurs more adverse lipid profiles worldwide unless the
obesity epidemic is controlled.
This study has multiple limitations as well as strengths.
The variable and low response rates in some cohorts make
the data tenuous but the age-structure of the studied
cohorts was similar to the local populations and therefore
the data can be generalized for evaluation of risk factor
trends. Small number of subjects in each of the studies
and age-specific subgroup could also be concern but the
sample sizes have been determined using available recom-
mendations for the prevalence of cardiovascular risk fac-
tors in a community [41] and are considered appropriate
for inter-group comparisons. We have determined both
age-adjusted mean levels of various lipoproteins as these
could be earliest population-level change and these show
significant trends. Prevalence rates are robust evidence of
population level change and the present study using sim-
ple meta-regression techniques shows significant trends in
important lipid abnormalities. This type of meta-regres-
sion is used for combining clinical trials as well as epide-
miological studies using pre-defined end points [42].
Generalizability of the study results to the local urban
population or to the whole country may not be appropri-
ate at this time as socioeconomic structure of the country
is so different from locality to locality and town to town
[43]. A major strength of the study is use of similar assess-
ment methodologies that make the observations compa-
rable. Another strength is determination of different types
of lipoprotein abnormalities and cholesterol ratios which
have emerged as important risk factor. The study defini-
tively shows that biological risk factors (lipids) are caus-
ally related to increasing obesity and to increasing
socioeconomic status as measured by educational status.
It has been previously reported that up to a certain level of
socioeconomic status (gross national product) the risk
factors tend to increase and once a particular per capita
income is achieved the risk factors tend to decline with
increasing socioeconomic status [44]. Indeed, a more
careful assessment of the trends of dyslipidemias (Figure
3) reveals that risk factors in educated Indian middle-class
subjects may be starting to level-off as observed in JHW-3
and JHW-4 studies. This indicates importance of evolving
socioeconomic changes as an important driver as well as
controller of cardiovascular diseases [44].
Low HDL cholesterol and high total:HDL cholesterol are
important cardiovascular risk factors. Multiple prospec-
tive studies have identified the importance of low HDL
cholesterol as cardiovascular risk factor [25]. Importance
of total:HDL ratio has been highlighted in the Physicians
Health Study that reported relative risk (RR) of acute myo-
cardial infarction in the top vs. bottom quintile of
total:HDL cholesterol ratio was 3.73 (95% confidence
interval 1.95–7.12) and was substantially greater than
total cholesterol (RR 1.86; 1.05–3.28), HDL cholesterol
(0.38; 0.21–0.69), and apolipoprotein B (2.50; 1.31–
4.75) [45]. The INTERHEART Study also reported that
ratio of apolipoprotein B/A1 was the most important risk
factor for acute myocardial infarction in South Asians
[46]. It has also been reported that in patients receiving
statin therapy levels of non-HDL cholesterol, apolipopro-
tein B, and total:HDL cholesterol ratio of ≥ 4.0 were more
important than other lipid parameters [47]. Increasing
ratio in this Indian urban population along with increas-
ing non-HDL cholesterol and falling HDL cholesterol lev-
els associated with increasing socioeconomic status and
obesity shows the appropriate direction for prevention
effort. Increasing socioeconomic status of Indians has to
be complemented with intensive public health education
and policy changes at the national level [2,48] for cardio-
vascular disease prevention.
In conclusion, this report is first in a low income country
– India- that demonstrates cross-sectional and longitudi-
nal trends in dyslipidemia and its causal relationship with
adiposity and socioeconomic status. Data analysis of such
a cohort reveals non-similarities (increasing non-HDL
cholesterol, triglycerides, and total-HDL ratio) as well as
similarities (increasing socioeconomic status and obesity)
vis-à-vis other developing and developed regions of the
world [49]. The inferences that can be translated for impli-
cations to health care policies and practice, medical edu-
cation and research is beyond the scope of this
publication.
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